...NewAge BIOTECH Enter the Business Name BUSINESS PLAN Business Plan Prepared By Gerald Sawyer, PhD. Enter your full name Enter your title Enter the company name Enter the company address Enter City, State, and Zip Code Enter the phone/fax number(s) Enter your e-mail and Web addresses Date Prepared January 200B Enter Month and Year Insert your company’s disclaimer and confidentiality notice. Consult with your attorney as to the wording. The information contained herein is furnished on the condition that it is solely for internal use, for evaluation and planning purposes only, and this information shall not be disclosed, duplicated, used in whole or in part, for any other reason whatsoever. TABLE OF CONTENTS To jump directly to any title listed in the Table of Contents, hold down CTRL and then click the title. TABLE OF CONTENTS 2 Executive Summary 5 The Company 5 The Market 5 Competitive Analysis 5 The Product/Service 5 Value Proposition 6 Marketing and Sales Plan 6 Management and Organization 6 Financial Summary 6 Investor Summary 6 The Company 8 Name and Location 8 Facilities 8 Legal Form of Business 8 Employees 8 Company History 8 Marketing Plan 9 Industry Profile 9 Current Size 9 Growth Potential 9 Industry Trends 9 Other Characteristics 10 Sales Channels...
Words: 12336 - Pages: 50
...NewAge BIOTECH Enter the Business Name BUSINESS PLAN Business Plan Prepared By Gerald Sawyer, PhD. Enter your full name Enter your title Enter the company name Enter the company address Enter City, State, and Zip Code Enter the phone/fax number(s) Enter your e-mail and Web addresses Date Prepared January 200B Enter Month and Year Insert your company’s disclaimer and confidentiality notice. Consult with your attorney as to the wording. The information contained herein is furnished on the condition that it is solely for internal use, for evaluation and planning purposes only, and this information shall not be disclosed, duplicated, used in whole or in part, for any other reason whatsoever. TABLE OF CONTENTS To jump directly to any title listed in the Table of Contents, hold down CTRL and then click the title. TABLE OF CONTENTS 2 Executive Summary 5 The Company 5 The Market 5 Competitive Analysis 5 The Product/Service 5 Value Proposition 6 Marketing and Sales Plan 6 Management and Organization 6 Financial Summary 6 Investor Summary 6 The Company 8 Name and Location 8 Facilities 8 Legal Form of Business 8 Employees 8 Company History 8 Marketing Plan 9 Industry Profile 9 Current Size 9 Growth Potential 9 Industry Trends 9 Other Characteristics 10 Sales Channels...
Words: 12336 - Pages: 50
...clients in the pharmaceutical industry? Question 1: Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. PESTEL analysis of the macro-environment surrounding the pharmaceutical industry: As a reminder: Macro-environment: PESTEL Industry (or sector): 5 forces of Porter + Life cycle THE PESTEL MODEL: 1. Political 2. Social 3. Environmental 4. Economic 5. Techonological 6. Legal SOCIAL FACTORS Ageing population: need more drugs Better informed customers: Firms should give more information, because when you’re sick the first thing you think of doing is looking up on the internet. Firms have to work on their communication Social responsibility: related to medications that are meant to cure people. How much money should be made from drugs that are saving lives? At which point should firms renounce to their huge benefits? Importance of emerging markets: some regions in Asia More: New industries for new diseases, geographical differences (some countries don’t have money to spend on drugs) ECONOMIC FACTORS Globalisation: market is going global concerning drugs and pharmaceutical products Wave of M&A: correlated factor with globalisation Different required capabilities of each category of drugs: ethical drugs, OTC, generics, biotech, vaccines Conterfeit medicines: possible to buy it online TECHNOLOGICAL FACTORS: Uncertainty and complexity of the R&D process...
Words: 925 - Pages: 4
...Executive Summary The purpose of this paper is to analyze the best exit route that would help Adnexus continue its objective of developing therapeutics compounds. First, analysis will be made on the biotechnology marketspace. Then, light will be shed on the internal and external environments of Adnexus. Then, discussion will be made on the company’s current status and available solutions. Finally, recommendation and action plans will be devised on the best route for Adnexus. The company competes in the biotechnology industry. A large portion of the market (65%) is controlled by fewer players. The market is characterized by high R&D spending. Adnexus had a successful strategic partnership with Bristol-Myers Squibb (BMS), and leadership was considering weather to further negotiate an acquisition deal with them or instead, go public. One of Adnexus key problems was the struggle to generate a study revenue stream. This is why the company has to decide on an exit route that will generate high liquidity and preserve its mission. Recommended course of action is to take the acquisition exit route. First, on average an IPO can generate up to $52.6 million, which is not enough for Adnexus expenses and operations needs. Prior to acquisition offer, BMS offered Adnexus a deal of $1.5 billion. This is why for an acquisition the company might be welling to pay more. Going public is a costly process, and public companies obligated to comply with higher regulatory standards. With a well devised...
Words: 1577 - Pages: 7
...and herb extract markets. However, it faced fierce competition in the collagen market which was already dominated by a number of large multinational firms, and in the herb extract market in which competition was becoming increasingly intense due to the rising number of imitators. This was a challenging situation for Holista CollTech Ltd. since these competitions could prevent the company from achieving its objective to increase its control in these two markets. 1. What were Holista CollTech’s businesses? What were the company’s long-term objectives? The Holista CollTech’s businesses can be divided into two catagories. The first business is R&D outputs and licensing. The company were a research-driven biotech company, a result of merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd dedicated to delivering first class natural ingredients and wellness products. Moreover, the company research, develops, manufactures and markets “healthstyle” products to address the unmet and growing needs of natural medicine. Holista CollTech...
Words: 5347 - Pages: 22
...The note centres on a descriptive overview of the predominant issues in the three major Triad market areas: the US, Europe and Japan (although major issues in emerging markets are also mentioned). The note covers the overall industry environment with in-depth discussion of the driving forces in the industry such as globalisation (in particular global regulatory issues, changing world demographics and worldwide pricing disparities); development of new technology; the importance of time to market; and amalgamations. The case also examines issues around corporate social responsibility. 2. Position of the Case The pharmaceutical industry case study lends itself to: • assessing an organisation’s competitive environment, using the following analysis frameworks: – PESTEL, – Porter’s five forces, – Scenario planning; • • • discussing issues around co-operation and alliance; establishing the role of critical (winner) products for big drug companies; assessing the role of ethics in corporate strategy; and 187 © Pearson Education...
Words: 8602 - Pages: 35
...Pharmaceutical Industry: New Drug Development Semester: 2012 Day of Week/Time: Office Hours: Class Website: Overview This course provides a detailed overview of the drug and biologics development process from discovery through regulatory approval. Special attention is given to the roles, functions and significance of the various disciplines involved in the R&D process, their interactions with each other, and the strategic management of these functions. Attention will also be given to key technologies used throughout the R&D process. The economics of pharmaceutical R&D as well as trends in licensing, outsourcing and partnerships will be covered. The student will gain an understanding of R&D strategy and the relationship between R&D and overall organizational success. Pedagogy The course will employ lectures notes, assigned readings, case analyses, individual homework assignments, and a final project. Each student will analyze three cases from the Harvard Business Review involving pharmaceutical companies. The final project will be a written paper touching on some aspect of managing pharmaceutical research and development. Relationship of Course to the Rest of the Curriculum The pharma value chain comprises all of the functional business elements from drug discovery through commercialization, and includes critical supporting functions, such as supply chain logistics and regulatory and compliance. IT is an enabler at the strategic...
Words: 2063 - Pages: 9
...Stephen Walker 2012 Leading in Innovation Stephen Walker 2012 Leading in Innovation Monsanto Company 800 N. Lindbergh Blvd. St. Louis, MO 63167 General Inquiries: (314) 694-1000 Media Inquiries: (314) 694-NEWS (6397) Monsanto Company 800 N. Lindbergh Blvd. St. Louis, MO 63167 General Inquiries: (314) 694-1000 Media Inquiries: (314) 694-NEWS (6397) Table of Contents Quantitative Analysis ………………………………..2 Performance Highlights …………………………….3 Trends……………………………………………………….4 Industry comparison………………………………….4 Qualitative Analysis……………………………………5 Sales Pitch ………………………………………………. .7 References…………………………………………………9 Monsanto Co. is a global provider of agricultural products and integrated solutions for farmers. We produce leading seed brands in large-acre crops like corn, cotton, and oilseeds (soybeans and canola), as well as small-acre crops like vegetables. We also produce leading in-the-seed trait technologies for farmers that are aimed at protecting their yield, supporting their on-farm efficiency and reducing their on-farm costs (About, 2012). It is because of these traits Monsanto Company is number one provider of seeds. In the United States, that meant offering more choices: more products at more price points in corn, more options in soybeans and improved products in both. The result speaks volumes. We still have more to do, yet our primary new U.S. products—the Genuity reduced-refuge family in corn and Genuity Roundup Ready 2 Yield soybeans—stepped...
Words: 1848 - Pages: 8
...NEW VENTURE CREATION CASE STUDY: OPPORTUNITY RECOGNITION AT OPHL QUESTION 1 Why did the recognizing a new business opportunity was important for OPHL? It is very crucial for OPHL in recognizing new business opportunity especially when the company is realize the business turning to be unusual, thus effected the profit. In order OPHL to sustain in the industry, the company must seek a new business opportunity which promises a huge profit for short and long term, thus create values to the stakeholders. OPHL is facing turbulent business environment and it requires the company to be more aggressive and creative to ensure the sustainability of OPHL. The importance of recognizing new business opportunity has mentioned by Peter Drucker in his theories of Business Diamond Model and Managerial Levers. OPHL also needs to think out of the box in searching new opportunity to be competitive in the market as mentioned by Michael Porter in his Diamond Model. In that theory, Porter says that there are six broad factors; factor conditions, demand conditions, related and supporting industries, firm strategy, structure and rivalry, government and chance, which has become a key tools that interact with each other to create conditions where innovation and improved competitiveness occurs. QUESTION 2 What is the dilemma faced by Mrs. Rahmah? What are the main opportunities identified by OPHL? A recession led to slowdown in economic activity and due to the economic downturn, the...
Words: 2800 - Pages: 12
...Developing & Implementing a Measurable Strategic Performance Management Framework and Automated Balanced Scorecard in a Medical Devices Company [pic] Implementation Case Study Becton Dickinson ANZ Copyright This publication is © Copyright 2004 ASVP Consulting Pty Ltd with all rights reserved. Except to the extent of the uses permitted under the Copyright Act 1968, no part of this publication may be reproduced or transmitted in any form or by any means including information storage and retrieval systems, without the prior written consent of ASVP Consulting Pty Ltd. Trade Marks Advanced Strategic Value Propositions™ is a trade mark of ASVP Consulting Pty Ltd. PulseSuite®, PulseManager®, PulseFinder® and Primed Online® are registered trade marks of Primed Online Pty Ltd. PulseProject™ is a trade mark of Primed Online Pty Ltd. Becton Dickinson, BD, and Helping All People Lead Healthy Lives are trademarks of Becton Dickinson Pty Ltd. Acknowledgements The kind assistance of Michael Lyon, CEO and the management team of BD Australia, and Grant Alecock, General Manager, and the management team of BD NZ is gratefully acknowledged. ASVP Consulting Pty Ltd ASVP Consulting Pty Ltd has written this independent case study on the implementation of a Balanced Scorecard Framework Solution in order to quantify the benefits accruing to BD and to highlight the potential benefits available to other organisations considering the implementation...
Words: 9670 - Pages: 39
...INTRODUCTION Merck & Company : Evaluating the Licensing Opportunity Various recently-born biotech companies sell their technologies in either finished or early stage to bigger companies in need of financing capital to preceed business, while those bigger companies acquire technologies to scout for promising profitable business. This sort of process needs numbers of decision makings and agreements from both parties on the valuation methods is crucial here. The valuation method being used has to hold objective validity and generality. For the managers to make accurate forecast of future profitability in managing companies, quantified decision making process is needed. Here we are dealing about whether Merck should give financial support to the R&D project of Davanrik offered by LAB, and about the process of valuation and the final decision. First we are to make brief of LAB’s business proposal and practice detailed valuation functions to decide if the proposal is profitable or not. And finally we will make a decision based on the valuation process in perspective of Rich Kender, Vice President of Financial Evaluation & Analysis of Merck. Brief introduction of Merck and its agenda regarding Davanrik project As a world-class pharmaceutical company concentrated on R&Ds, Merck is performing various researches and developments upon medical supplies for human and animals. Merck is providing Pharmaceutical Benefit Management (i.e. PBM) through a company called Merck-Medco...
Words: 1134 - Pages: 5
...Revenue Recognition (Topic 605) An Amendment of the FASB Accounting Standards CodificationTM No. 2009-13 October 2009 Multiple-Deliverable Revenue Arrangements a consensus of the FASB Emerging Issues Task Force The FASB Accounting Standards CodificationTM is the single source of authoritative nongovernmental U.S. generally accepted accounting principles. An Accounting Standards Update is not authoritative; rather, it is a document that communicates the specific amendments that change the Accounting Standards Codification. It also provides other information to help a user of U.S. GAAP understand how and why U.S. GAAP is changing and when the changes will be effective. For additional copies of this Accounting Standards Update and information on applicable prices and discount rates contact: Order Department Financial Accounting Standards Board 401 Merritt 7 PO Box 5116 Norwalk, CT 06856-5116 Please ask for our Product Code No. ASU2009-13. FINANCIAL ACCOUNTING SERIES (ISSN 0885-9051) is published quarterly by the Financial Accounting Foundation. Periodicals postage paid at Norwalk, CT and at additional mailing offices. The full subscription rate is $230 per year. POSTMASTER: Send address changes to Financial Accounting Standards Board, 401 Merritt 7, PO Box 5116, Norwalk, CT 06856-5116. | No. 325 Copyright © 2009 by Financial Accounting Foundation. All rights reserved. Content copyrighted by Financial Accounting Foundation may not be reproduced, stored...
Words: 17927 - Pages: 72
...operates directly or through established joint ventures and provides pharmaceutical management services (PBM). During the last 5 years the company has launched 15 new successful products; the most popular drugs generated the amount of $5.7 billion in worldwide sales. Between 1998 and 1999 a 20% increase in sales was observed. Merck owns patents on their most popular drugs, however they will expire by 2002. Once the patents are expired, sales will decline when generic cheap substitutes enter the market. The company aims at maintaining a healthy pipeline in the drug development, by constantly refreshing their portfolio, thus preventing the loss of sales from drugs going off patent. New drugs are either developed by internal research (the majority) or through collaboration with biotech companies. The product: Davanrik Davarnik was developed by LAB Pharmaceuticals, a small and relatively young pharmaceutical concern specialized in compounds for the treatment of neurological disorders. Originally it was meat for the treatment of depression. Apart from acting on receptors involved in causing depression it also seemed to block the receptor in CNS responsible for appetite. It is currently in pre-clinical development, ready to enter the FDA clinical approval process consisting of three phases. Problem definition An opportunity occurred to license the drug Davanrik, with the potential to treat both depression and obesity, from a small pharmaceutical concern, LAB Pharmaceuticals, that was...
Words: 511 - Pages: 3
...2. Environment Analysis 2a. Macro-environment factors Singapore Being a member of Association of Southeast Asian Nations (ASEAN) and Asian Pacific Economic Cooperation (APEC) (CIA World Fact book, 2011). Has help businesses pay less import tariffs or custom duties. The low crime rate and strong police force in Singapore (Singstats, 2013) is safe for long hours operation, while legislation under Agri-Food and Veterinary Authority of Singapore (AVA) determine the equality of food served to customers, and issuing licence to handle food are the policies that must be followed. Singaporeans is also more health conscious due to active health awareness campaign by Health Promotion Board (HPB). Technological such as genetically modified food (GM foods or biotech foods) are foods produced from genetically modified organisms might affect the quality of the food produce. 2b. Micro-environment factors The supplier can create an advantage and disadvantage to Rochor Beancurd House’s (RBH) business operations. One of the advantages for RBH is to negotiate for cheaper and better quality raw materials from supplier. The type of customers affecting our businesses can be categories into students, working adults and gender. 2c. Competitive Strategy Competitors in the market usually compete against one another by deploying different marketing mix strategy in product, pricing, place and promotion (Appendix 1). RBH’s competitive advantage against competitors is to maintain the high standard...
Words: 536 - Pages: 3
...head: GAP ANALYSIS: INTERSECT INVESTMENTS Gap Analysis: Gene One Stacy Starkes University of Phoenix May 17, 2010 Gap Analysis: Intersect Investments Gene One is a ground-breaking Biotech organization that has been faced with many issues. The organization has been forced to expand at a rapid rate to meet the organizational goals of becoming one of the leading organizations in the biotech industry. In order to compete with the ever increasing biotech industry, the CEO and the board of directors believe that going public within the next three years would be beneficial for the organization. By making the appropriate choices of becoming a publically traded organization, Gene One will bark upon a journey that will help them to revolutionize and to use cutting edge technology of eliminating pesticides on tomatoes and potatoes to meet the organizational goals. The rapid growth rate took the organization from a small $2 million start-up company to more than a $400 million in annual sales. Therefore, by implementing an IPO strategy and implementing other strategic goals will help fulfill the organizations growth target and prove the organization is worthy of its capabilities. In addition, the method of benchmarking can help Gene One to succeed and enable the organization to find the necessary solutions to the most pressing and immediate issues. According to The Benchmarking Exchange (2010), “Benchmarking is the process of measuring an organization's internal processes then...
Words: 3263 - Pages: 14
